// App-Quantinova.ai

4561 : Health-related quality of life (HRQoL) for patients with advanced/metastatic urothelial carcinoma (UC) enrolled in KEYNOTE-052 who are potentially platinum ineligible.

Researchers

Presenter

  • Rafael Morales-Barrera

Principal Investigators

  • Peter H. O'Donnell

  • Petros Grivas

  • Jacqueline Vuky

  • Thomas Powles

  • Kylea R. Potvin

  • Susanna Y. Cheng

  • Eli Rosenbaum

  • Noah M. Hahn

  • Daniel Keizman

  • Fausto Roila

  • Jose Luis Perez-Gracia

  • Elizabeth R. Plimack

  • Ronald De Wit

  • Jin Zhi Xu

  • Kentaro Imai

  • Haojie Li

  • Josephine M. Norquist

  • Joaquim Bellmunt

Medical Centers

  • Department of Hematology, Vall dHebron Institute of Oncology, Vall dHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • The University of Chicago Medical Center, Chicago, IL

  • University of Washington, Seattle, WA

  • Oregon Health and Science University, Portland, OR

  • Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • London Regional Cancer Centre, London, ON, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Rabin Medical Center, Petach Tikvah, Israel

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Meir Medical Center, Kfar-Saba, Israel

  • Azienda Ospedaliera S.Maria, Terni, Italy

  • Clinica Universitaria de Navarra, Navarra, Spain

  • Fox Chase Cancer Center, Temple Health, Philadelphia, PA

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • Merck & Co., Inc., Kenilworth, NJ

  • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

Locations

  • Spain

  • United States

  • United Kingdom

  • Canada

  • Israel

  • Italy

  • Netherlands

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Creatinine

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • NCT02335424

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved